Nurses Revision

diabetes mellitus pancreas that produces insulin

Diabetes Insipidus (Arginine Vasopressin Deficiency & Resistance)

Text size
On this page

Overview and Definition

Diabetes Insipidus (DI) is a water-balance disorder characterized by the excretion of abnormally large volumes of dilute (hypotonic) urine (polyuria) accompanied by excessive thirst and fluid intake (polydipsia). It results from either a deficiency in the production or release of arginine vasopressin (AVP)—also called antidiuretic hormone (ADH)—or the inability of the renal collecting ducts to respond to AVP.

In 2022–2024 international endocrinology consensus terminology, the major forms of diabetes insipidus were renamed to prevent confusion with diabetes mellitus: central DI is now termed Arginine Vasopressin Deficiency (AVP-D), and nephrogenic DI is termed Arginine Vasopressin Resistance (AVP-R). Both names remain widely tested in nursing and medical examinations.

Why "Insipidus" vs. "Mellitus"?

Both disorders present with polyuria and polydipsia, but their mechanisms are completely different. Diabetes mellitus ("honey-sweet") causes osmotic diuresis from excess glucose in the urine (hyperglycemia & glycosuria). Diabetes insipidus ("tasteless/watery") causes free-water diuresis with dilute, colourless urine that contains no glucose and is driven by defective AVP signaling.

Normal Water Physiology and Pathophysiology

Normal AVP (ADH) Physiology

  1. Synthesis and Storage: AVP is synthesized as a prohormone (alongside copeptin, its stable C-terminal glycopeptide) in the magnocellular neurons of the hypothalamic supraoptic and paraventricular nuclei. It travels down the hypothalamo–hypophyseal tract to be stored in and released from the posterior pituitary gland (neurohypophysis).
  2. Triggers for Release:
    • Osmotic Stimulus (Primary): Sensitive hypothalamic osmoreceptors trigger AVP release when plasma osmolality rises above ~280–285 mOsm/kg.
    • Baroreceptor Stimulus: Arterial and atrial baroreceptors trigger massive AVP release during significant intravascular volume depletion (≥ 8–10% fall in blood volume or hypotension).
  3. Renal Action: Circulating AVP binds to V2 receptors on the basolateral membrane of principal cells in the renal collecting ducts, activating adenylate cyclase and intracellular cyclic AMP (cAMP). This triggers the insertion of aquaporin-2 (AQP2) water channels into the luminal membrane, allowing free water to be reabsorbed back into the hypertonic renal medulla and producing concentrated urine.

Pathophysiology of Diabetes Insipidus

When AVP is absent (AVP-D), rapidly destroyed (gestational DI), or fails to activate V2/AQP2 channels (AVP-R), the collecting ducts remain impermeable to water. Free water is lost continuously into the urine (urine osmolality typically < 300 mOsm/kg and specific gravity < 1.005), raising plasma osmolality and serum sodium (hypernatremia). In conscious patients with intact hypothalamic thirst centers and free access to water, compensatory polydipsia keeps serum sodium near normal; however, if thirst is impaired or water is withheld, life-threatening hypernatremic dehydration develops rapidly.

Classification and Types of Diabetes Insipidus

1. Central Diabetes Insipidus (AVP Deficiency / AVP-D)

Caused by inadequate synthesis, transport, or secretion of AVP from the hypothalamus or posterior pituitary (usually > 80–90% of AVP-producing neurons must be damaged before overt polyuria appears).

  • Acquired Causes (Most Common):
    • Head Trauma and Neurosurgery: Traumatic brain injury (TBI), basilar skull fractures, and transsphenoidal pituitary surgery or craniotomy. Post-operative DI may follow a classic triphasic response: (1) acute transient DI (stunning of neurons), (2) transient SIADH around days 4–10 (uncontrolled AVP dumping from degenerating axons causing hyponatremia), and (3) permanent DI if > 80–90% of neurons are destroyed.
    • CNS Tumours: Craniopharyngioma (especially in children), pituitary macroadenoma, germinoma, meningioma, and brain metastases (breast or lung).
    • CNS Infections & Vascular Insults: Bacterial or tuberculous meningitis, viral encephalitis, cerebral abscess, Sheehan syndrome (postpartum pituitary necrosis), hypoxic–ischemic encephalopathy, and intracranial aneurysms.
    • Infiltrative, Autoimmune, & Idiopathic: Lymphocytic infundibuloneurohypophysitis, Langerhans cell histiocytosis, neurosarcoidosis, and idiopathic (~20–30% of cases).
  • Congenital / Genetic Causes: Autosomal dominant mutations in the AVP gene and Wolfram syndrome (DIDMOAD)—an autosomal recessive disorder combining Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, and Deafness.

2. Nephrogenic Diabetes Insipidus (AVP Resistance / AVP-R)

Endogenous AVP secretion is normal or elevated, but the renal collecting ducts fail to concentrate urine in response to AVP.

  • Acquired Causes (Most Common in Adults):
    • Medications: Lithium is the leading drug cause (enters collecting duct principal cells via epithelial sodium channels [ENaC] and downregulates AQP2 expression, affecting up to 20–40% of chronic users); others include demeclocycline, amphotericin B, foscarnet, cidofovir, cisplatin, and rarely tenofovir/ifosfamide.
    • Electrolyte Abnormalities: Chronic hypercalcemia (impairs AQP2 insertion and loop of Henle concentrating gradient) and severe hypokalemia (causes tubular vacuolization and reduced AQP2).
    • Renal Parenchymal & Obstructive Disorders: Chronic kidney disease, polycystic kidney disease, sickle cell nephropathy (medullary ischemia), amyloidosis, Sjögren syndrome, and post-obstructive diuresis after relief of urinary tract obstruction.
  • Congenital / Hereditary NDI: Presents in infancy (often male neonates): ~90% are X-linked recessive mutations in the V2 receptor gene (AVPR2), and ~10% are autosomal recessive/dominant mutations in the AQP2 water channel gene.

3. Gestational Diabetes Insipidus (gAVP-D)

A rare, transient pregnancy complication (~1 in 30,000 pregnancies) typically presenting in the late second or third trimester and resolving spontaneously 4–6 weeks after delivery.

  • Mechanism: Placental trophoblasts produce high levels of vasopressinase (cysteine aminopeptidase), an enzyme that rapidly degrades circulating endogenous AVP. It is exacerbated in twin pregnancies or by impaired hepatic clearance of vasopressinase in pre-eclampsia, HELLP syndrome, or acute fatty liver of pregnancy (always check liver function tests in pregnant patients with new polyuria!).
  • Therapeutic Distinction: Gestational DI responds promptly to synthetic desmopressin (DDAVP) because desmopressin's altered N-terminal structure makes it resistant to degradation by placental vasopressinase (unlike natural vasopressin).

4. Primary Polydipsia (Differential "Polyuria–Polydipsia Syndrome")

Not a true deficiency or renal resistance to AVP, but an important mimic where excessive water intake comes first, expanding plasma volume, lowering serum osmolality, and physiologically suppressing endogenous AVP to cause secondary polyuria:

  • Dipsogenic DI: Abnormal lowering of the hypothalamic osmotic thirst threshold (patients feel genuinely thirsty at normal/low plasma osmolality due to hypothalamic trauma, granulomatous disease, or idiopathic causes).
  • Psychogenic Polydipsia: Compulsive water drinking seen in psychiatric illnesses (e.g., schizophrenia, obsessive–compulsive disorders) or with dry-mouth–inducing psychotropic drugs, carrying a high risk of acute hyponatremia.

Comparison of Polyuria–Polydipsia & Water-Balance Disorders

FeatureCentral DI (AVP-D)Nephrogenic DI (AVP-R)Gestational DIPrimary Polydipsia
Primary DefectDecreased hypothalamic/pituitary AVP secretionRenal collecting duct resistance to AVPExcess placental vasopressinase destroying AVPExcessive oral water intake suppressing AVP
Serum Na+ & OsmolalityHigh-normal or elevated (> 145 mmol/L if water restricted)High-normal or elevated (> 145 mmol/L if water restricted)High-normal or elevatedLow-normal or low (hyponatremia)
Endogenous AVP / CopeptinLowHigh (markedly elevated)Low (rapidly cleared)Low/suppressed at baseline, rises normally with hypertonicity
Response to Water DeprivationUrine stays dilute (or concentrates partially in partial CDI)Urine stays dilute (< 300 mOsm/kg)Urine stays diluteUrine concentrates (> 600 mOsm/kg)
Response to DesmopressinConcentrates urine (> 50% rise in urine osmolality)No/minimal response (< 10% rise in complete NDI)Concentrates urine (DDAVP resists vasopressinase)Not indicated (risk of severe hyponatremia)
ParameterDiabetes Insipidus (DI)Diabetes Mellitus (DM)SIADH (Opposite of DI)
Hormone DefectDeficient or ineffective AVP (ADH)Deficient or ineffective InsulinExcessive / inappropriate AVP secretion
Urine OutputMarkedly increased (polyuria > 3 L/day)Increased (osmotic polyuria)Decreased / concentrated
Urine Specific Gravity & OsmolalityVery low (< 1.005; < 300 mOsm/kg)High (> 1.020 due to glucose)High (> 1.020; > 100–300 mOsm/kg)
Blood GlucoseNormalElevated (≥ 11.1 mmol/L random / ≥ 7.0 fasting)Normal
Serum SodiumNormal or Hypernatremia (> 145 mmol/L)Variable (pseudohyponatremia or hypernatremia in HHS)Hyponatremia (< 135 mmol/L)

Advertisements

Clinical Manifestations

  • Adults and Older Children:
    • Profuse Polyuria: Sudden onset (classic in traumatic/post-surgical AVP-D) or gradual onset of 3 to 15+ litres/day of pale, dilute, water-like urine.
    • Intense Polydipsia: Persistent thirst, often with a striking craving for ice-cold water.
    • Nocturia and Sleep Disruption: Frequent awakening at night to urinate and drink water, leading to daytime fatigue and irritability.
  • Infants and Young Children (Often Congenital NDI or Craniopharyngioma): Inconsolable crying/irritability that settles with plain water rather than milk feeds, unexplained fever, vomiting, constipation, poor weight gain (failure to thrive), soaked diapers, and developmental delay from repeated hypernatremic episodes.
  • Signs of Dehydration & Hypernatremia (When Fluid Access or Thirst Is Impaired): Dry mucous membranes, poor skin turgor, sunken eyes/fontanelle, tachycardia, orthostatic hypotension, weight loss, confusion, lethargy, muscle twitching, hyperreflexia, seizures, and coma (common in ICU, head-injured, sedated, or adipsic patients).
  • Underlying Cause Signs: Visual field defects (bitemporal hemianopia) or headaches from pituitary/hypothalamic tumours, or anterior pituitary hormone deficiencies (hypothyroidism, adrenal insufficiency).

Diagnostic Workup and Special Tests

Diagnosing diabetes insipidus follows a safe, stepwise clinical algorithm—first proving hypotonic polyuria, then excluding common mimics, and finally distinguishing AVP-D, AVP-R, and primary polydipsia.

  1. Step 1 — Confirm Hypotonic Polyuria & Exclude Osmotic Diuresis:
    • Measure 24-hour urine volume: > 3 L/day (or > 50 mL/kg/24 h) in adults, or > 2 L/m2/day (> 4 mL/kg/hr) in children.
    • Verify hypotonic urine: urine osmolality < 300 mOsm/kg and urine specific gravity < 1.005.
    • Rule out diabetes mellitus (blood/urine glucose), hypercalcemia (serum calcium), hypokalemia (serum potassium), and renal disease (creatinine/BUN).
  2. Step 2 — Baseline Serum Sodium & Osmolality Check (Safety Gate):
    • If baseline serum Na+ > 145 mmol/L and serum osmolality > 295 mOsm/kg while urine remains dilute (< 300 mOsm/kg), DI is already biochemically evident. Do NOT perform water deprivation (it is dangerous and unnecessary); administer desmopressin directly to differentiate AVP-D from AVP-R.
    • If baseline serum Na+ is low (< 135 mmol/L), primary polydipsia is strongly favored.
  3. Step 3 — Supervised Water Deprivation Test + Desmopressin Challenge:

    Performed in hospital under strict clinical supervision (fasting from all fluids beginning in the morning, with hourly body weight, BP/HR, urine volume, urine osmolality, and serial serum Na+/osmolality). Stop deprivation immediately if body weight drops by > 3–5%, serum Na+ exceeds 145–150 mmol/L, urine osmolality exceeds 600 mOsm/kg (rules out DI), or urine osmolality plateaus (< 30 mOsm/kg change over 2–3 consecutive hours) despite rising plasma osmolality (≥ 295 mOsm/kg). Then give Desmopressin (2 μg IV/SC or 10 μg intranasally) and measure urine osmolality over the next 2 hours.

  4. Step 4 — Copeptin-Stimulation Testing (Modern Reference Standard Where Available):

    Direct AVP assays are technically unstable; copeptin is secreted in an equimolar 1:1 ratio with AVP and is highly stable. A baseline unstimulated copeptin > 21.4 pmol/L reliably diagnoses Nephrogenic DI without needing fluid restriction. Where available, hypertonic saline–stimulated copeptin (at Na+ ≥ 150 mmol/L; cutoff ≤ 4.9 pmol/L confirms AVP-D with ~96.5% accuracy) or arginine-stimulated copeptin outperforms the traditional water deprivation test in distinguishing partial AVP-D from primary polydipsia.

  5. Step 5 — Etiological Localization (MRI & Ancillary Workup):

    Once AVP-D is confirmed, obtain a contrast-enhanced MRI of the brain/pituitary (typically shows loss of the normal posterior pituitary T1 "bright spot", stalk thickening, or mass lesions) and evaluate anterior pituitary hormones (cortisol, TSH/free T4, prolactin, IGF-1). For AVP-R, perform renal ultrasound (to exclude hydronephrosis/obstructive uropathy), drug levels (lithium), and genetic testing if congenital.

DiagnosisUrine Osmolality After Water DeprivationUrine Osmolality Change After Desmopressin
Normal / Primary PolydipsiaConcentrates (> 600–800 mOsm/kg)< 10% further rise (DDAVP unnecessary if > 600)
Complete Central DI (AVP-D)Remains dilute (< 300 mOsm/kg)> 50% increase (often > 100%)
Partial Central DI (Partial AVP-D)Partially concentrates (300–600 mOsm/kg)10% – 50% increase (or > 9–10% up to 50%)
Complete Nephrogenic DI (AVP-R)Remains dilute (< 300 mOsm/kg)< 10% increase (stays < 300 mOsm/kg)

Advertisements

Medical and Pharmacological Management

1. Fluid Resuscitation and Hypernatremia Safety Rules

  • Intact Thirst + Alert Patient: Allow free, unrestricted access to oral water guided by thirst—in mild/partial DI, drinking to thirst alone may prevent dehydration.
  • Hypotension / Hypovolemic Shock: Restore intravascular circulation first with isotonic 0.9% Normal Saline until blood pressure and perfusion stabilize.
  • Correction of Hypernatremia (Unable to Drink): Replace the free-water deficit using IV 5% Dextrose in water (D5W) or 0.45% NaCl (or NG/oral water if safe). Critical Safety Limit: In chronic hypernatremia (> 48 h), lower serum sodium gradually by no more than 8–10 mmol/L per 24 hours (~0.5 mmol/L/hr) because rapid free-water shifts cause fatal cerebral edema.

2. Pharmacological Therapy for Central DI (AVP-D) & Gestational DI

  • Desmopressin (DDAVP — Drug of Choice): Synthetic V2-selective analogue of AVP with prolonged antidiuretic duration (6–14 hours) and negligible vasopressor effect.
    • Routes & Typical Adult Antidiuretic Dosing: Oral tablets (0.1–0.2 mg 1–3 times daily), sublingual melt (60–120 μg 1–3 times daily), intranasal spray/solution (10–20 μg 1–2 times daily), or parenteral SC/IM/IV (1–4 μg daily in 1–2 divided doses; acute post-op/ICU doses often start at 0.5–2 μg IV/SC repeated only when polyuria recurs).
    • Preventing Water Intoxication: Patients must drink only when thirsty while taking desmopressin and allow a brief period of breakthrough polyuria ("aquaresis") at least once daily or weekly (delaying the next dose slightly until urine output increases) to prevent cumulative fluid retention and life-threatening dilutional hyponatremia.
  • Adjunctive / Historical Agents (Selected Partial CDI When Desmopressin Is Unavailable): Carbamazepine (enhances AVP release and renal sensitivity; monitor for hyponatremia/sedation) or chlorpropamide (potentiates AVP action, but rarely used today due to high risk of severe prolonged hypoglycemia).

3. Management of Nephrogenic DI (AVP-R)

Desmopressin is generally ineffective in complete NDI (very high doses are occasionally tried in partial NDI). Management targets the underlying trigger and lowers obligatory urine volume:

  • Treat Reversible Causes: Discontinue lithium (in consultation with psychiatry) or other offending nephrotoxins; correct hypercalcemia and hypokalemia; relieve urinary obstruction.
  • Low-Solute Diet: Restrict dietary sodium and excessive protein intake (while preserving adequate calories/protein for growing children)—lower renal solute excretion obligates less water loss in the urine.
  • Thiazide Diuretics (Paradoxical Antidiuretic Effect): Hydrochlorothiazide (e.g., 25–50 mg/day in adults or 1–2 mg/kg/day in children) reduces urine output by up to 30–50% by inducing mild extracellular volume depletion, which enhances proximal tubular sodium and water reabsorption so less filtrate reaches the AVP-resistant collecting duct.
  • Amiloride (Especially for Lithium-Induced NDI): A potassium-sparing ENaC blocker that prevents hypokalemia from thiazides and blocks lithium entry into collecting-duct principal cells.
  • NSAIDs (e.g., Indomethacin): Reduce renal prostaglandin E2 synthesis (prostaglandins normally antagonize water reabsorption), further reducing urine volume when combined with a thiazide; use cautiously with gastric and renal monitoring.

Pharmacokinetics and Pharmacodynamics of DI Medications

Drug & ClassPharmacodynamics (Mechanism)Pharmacokinetics (ADME)Key Nursing & Safety Implications
Desmopressin (DDAVP)
(Synthetic V2-Receptor Agonist)
Selectively stimulates renal collecting duct V2 receptors → increases cAMP → inserts AQP2 channels to concentrate urine; negligible V1 vasoconstrictor activity; resistant to placental vasopressinase.Bioavailability: 0.08–0.16% oral, ~10–20% intranasal (IV 10× more potent than intranasal). Onset: 15–30 min (IN/IV), ~60 min (PO); duration 6–14 h. Minimal hepatic metabolism; eliminated primarily unchanged by kidneys (t1/2 2–4 h, prolonged to ~9 h in severe CKD).Monitor serum Na+, urine output, and weight closely. Warn against drinking beyond thirst. Watch for hyponatremia symptoms (headache, nausea, confusion, seizures). Avoid in primary polydipsia.
Hydrochlorothiazide
(Thiazide Diuretic)
Inhibits Na+/Cl− cotransporter in distal convoluted tubule → mild volume contraction → increases proximal tubular Na+/water reabsorption, paradoxically reducing urine volume in NDI.Oral bioavailability ~60–70%; onset ~2 h, peak 4–6 h, duration 6–12 h; minimal metabolism, excreted unchanged in urine.Monitor serum K+, Na+, Mg2+, Ca2+ (causes hypokalemia and hypercalcemia), and BP. Combine with amiloride or low-salt diet to maximize antidiuresis and prevent hypokalemia.
Amiloride
(Potassium-Sparing Diuretic / ENaC Blocker)
Blocks epithelial sodium channels (ENaC) in late distal tubule/collecting duct; conserves K+ and blocks lithium uptake into principal cells.Oral bioavailability ~15–25% (take with food); peak 3–4 h; half-life 6–9 h; excreted unchanged in urine and feces.Monitor serum potassium for hyperkalemia (avoid K+ supplements or ACEIs/ARBs without close labs). First-line partner with HCTZ in lithium-induced NDI.
Indomethacin
(NSAID / COX Inhibitor)
Inhibits renal prostaglandin E2 synthesis, decreasing medullary blood flow and enhancing collecting-duct water reabsorption in NDI.Well absorbed orally (~100% bioavailability); highly protein-bound; hepatically metabolized; excreted in urine/bile (t1/2 ~4–5 h).Administer with food/PPI gastroprotection; monitor renal function (creatinine), GI bleeding, and blood pressure; avoid in dehydration or CKD.
Carbamazepine
(Anticonvulsant Adjunct)
Stimulates residual hypothalamic AVP release and enhances renal tubular sensitivity to AVP in partial AVP-D.Slow oral absorption; induces its own hepatic CYP3A4 metabolism (autoinduction); excreted in urine/feces.Monitor for hyponatremia, dizziness/ataxia, hepatotoxicity, and drug interactions via CYP3A4 induction.

Complications of Diabetes Insipidus

  • Acute Hypernatremic Dehydration & Hypovolemic Shock: Occurs when fluid losses exceed intake (especially in post-op, head-injured, elderly, or infant patients).
  • Neurological Injury: Cellular dehydration causes brain shrinkage, tearing bridging veins and risking intracranial/subdural hemorrhage, seizures, altered mental status, coma, and death.
  • Iatrogenic Treatment Complications:
    • Water Intoxication & Dilutional Hyponatremia: From excessive desmopressin dosing or drinking excess fluids without breakthrough urination (headache, vomiting, confusion, seizures).
    • Cerebral Edema: From lowering chronic hypernatremia too rapidly (> 8–10 mmol/L/24 h) with excessive hypotonic IV fluids.
  • Chronic Urological & Growth Complications: Non-obstructive hydronephrosis, hydroureter, and megacystis from lifelong high-volume urine flow (especially congenital NDI), and growth retardation/malnutrition in children whose stomachs stay constantly full of water.

Advertisements

Nursing Management of Diabetes Insipidus

Sample Nursing Care Plan for a Patient with Diabetes Insipidus (NANDA-I 2024–2026)

This care plan uses NANDA-I 2024–2026 diagnostic terminology (Inadequate fluid volume, Risk for impaired water-electrolyte balance, Impaired urinary elimination, Ineffective sleep pattern, and Inadequate health knowledge) prior to the detailed nursing interventions below.

AssessmentDiagnosis (NANDA-I 2024–2026)Planning (Goals & Outcomes)Implementation / InterventionsRationaleEvaluation
  • Subjective: Intense thirst, fatigue, dizziness on standing.
  • Objective: Urine output 350 mL/hr (> 8 L/24 h), urine specific gravity 1.002, dry mucosa, BP 94/60 mmHg, HR 116 bpm, acute weight loss.
Inadequate fluid volume (and Risk for shock) related to inability to concentrate urine secondary to AVP deficiency/resistance as evidenced by polyuria (350 mL/hr), hypotension, tachycardia, dry mucosa, and urine SG 1.002.

Restore fluid balance and hemodynamic stability within 12–24 hours.

Expected outcomes:

  • BP ≥ 100/65 mmHg, HR < 100 bpm, moist mucosa.
  • Daily weight stabilizes; urine output < 2.5–3 L/24 h (in CDI on therapy).
  1. Maintain strict hourly intake and output (I&O) charting and weigh patient daily at the same time on the same scale.
  2. Keep cold drinking water within easy reach if alert; infuse prescribed IV fluids (0.9% NaCl if shocked, then D5W/0.45% NaCl) if NPO/unconscious.
  3. Administer prescribed desmopressin (for CDI) or HCTZ/amiloride (for NDI) and monitor urine specific gravity every 2–4 hours.
  1. Tracks net fluid loss accurately; 1 kg sudden weight change equals ~1 L of fluid shift.
  2. Oral intake matching thirst protects against hypernatremia; IV access rescues patients unable to drink.
  3. Restores collecting-duct water reabsorption and confirms drug response via rising urine specific gravity (> 1.010).
After 24 hours, BP stabilized at 114/72 mmHg, HR dropped to 82 bpm, urine output fell to 1,900 mL/day, and weight stabilized.
  • Subjective: Post-pituitary surgery lethargy or risk during desmopressin/IV therapy.
  • Objective: Baseline serum Na+ 150 mmol/L (hypernatremia) or fluctuating serum osmolality during treatment.
Risk for impaired water-electrolyte balance related to massive free-water diuresis (hypernatremia) and risk of iatrogenic water intoxication from desmopressin or rapid hypotonic fluid replacement.

Safely normalize serum sodium without cerebral edema or hyponatremia.

Expected outcomes:

  • Serum Na+ decreases by ≤ 8–10 mmol/L/24 h into 135–145 mmol/L range.
  • No headache, confusion, or seizures.
  1. Monitor serum Na+, K+, and osmolality every 4–6 hours during acute correction or initiation of desmopressin.
  2. Perform regular neurological assessments (GCS, orientation, headache, nausea) for signs of cerebral edema or hyponatremia.
  3. Ensure mild breakthrough polyuria occurs before giving scheduled repeat desmopressin doses if Na+ trends downward.
  1. Prevents both over-correction cerebral edema (from rapid Na+ drop) and desmopressin-induced hyponatremia.
  2. Neurological symptoms are the earliest warning signs of dangerous osmotic brain shifts.
  3. Prevents cumulative water retention and dilutional hyponatremia.
Serum Na+ corrected safely from 150 to 140 mmol/L over 36 hours with intact GCS 15/15 and no seizures.
  • Subjective: Frequent urination every 30–60 minutes day and night.
  • Objective: Large-volume, pale, odourless urine; bladder distension risk in immobilized patients.
Impaired urinary elimination related to loss of renal urine-concentrating ability (AVP deficiency or resistance) as evidenced by high-volume frequency (> 3 L/day) and nocturia.

Reduce urinary frequency and protect renal/bladder integrity.

Expected outcomes:

  • Urine volume decreases toward normal (~1.5–2.5 L/day) and urine specific gravity rises > 1.008–1.010.
  • No bladder distension or perineal skin breakdown.
  1. Place bedside commode/urinal within reach and monitor for bladder distension or incomplete emptying.
  2. Check urine output and specific gravity each shift (and hourly in acute post-op cases).
  3. Administer prescribed antidiuretic medications (desmopressin or thiazide + amiloride) and maintain low-sodium diet in NDI.
  1. Prevents falls during urgent trips to the toilet and prevents urinary retention/hydronephrosis from massive volumes.
  2. Provides objective bedside proof of treatment response.
  3. Lowering renal sodium load in NDI reduces obligatory urine volume.
Urinary frequency decreased from hourly to every 4 hours with urine specific gravity 1.015 and no bladder distension.
  • Subjective: "I wake up 6–8 times every night to pass urine and drink water; I am exhausted."
  • Objective: Dark eye circles, daytime yawning, fragmented sleep log.
Ineffective sleep pattern related to severe nocturia and nighttime polydipsia as evidenced by 6–8 nocturnal awakenings and daytime fatigue.

Achieve uninterrupted restorative sleep periods by discharge.

Expected outcomes:

  • Patient experiences ≤ 1–2 nocturnal awakenings and sleeps ≥ 6–7 hours.
  • Patient reports feeling rested on awakening.
  1. Coordinate bedtime dosing of desmopressin (where prescribed for CDI) to control nocturnal polyuria safely.
  2. Cluster nursing care/observations during daytime hours when stable and keep a spill-proof water pitcher and urinal by the bedside.
  3. In partial DI, encourage meeting hydration needs steadily during daytime rather than large late-evening boluses (unless thirsty).
  1. Targeted nocturnal antidiuresis allows continuous REM/non-REM sleep cycles.
  2. Minimizes unnecessary sleep interruptions and fall hazards in the dark.
  3. Reduces nighttime bladder filling while preserving thirst-driven safety.
Patient slept 6.5 hours continuously with only 1 awakening and reported feeling markedly more rested.
  • Subjective: Patient asks whether DI means "sugar diabetes" and how to take nasal/oral desmopressin safely.
  • Objective: First-time diagnosis; no medical alert ID; unsure of hyponatremia or dehydration signs.
Inadequate health knowledge related to unfamiliarity with DI pathophysiology, desmopressin administration, and water-balance red flags as evidenced by patient questions about sugar diabetes and medication safety.

Demonstrate safe lifelong self-management prior to discharge.

Expected outcomes:

  • Patient explains DI vs. diabetes mellitus and demonstrates proper desmopressin use.
  • Patient states signs of both dehydration and water intoxication.
  1. Clarify that DI is a water/AVP disorder—not sugar diabetes—and demonstrate exact intranasal/oral desmopressin technique using teach-back.
  2. Teach the "drink to thirst" rule, daily morning weights, and waiting for mild breakthrough urination before repeat doses when advised.
  3. Teach warning signs of hypernatremia/dehydration (dry mouth, extreme thirst, dizziness) and hyponatremia/water intoxication (headache, nausea, confusion, weight gain), plus wearing a medical alert bracelet.
  1. Prevents inappropriate dietary sugar restriction and ensures consistent drug delivery (note nasal congestion reduces intranasal absorption).
  2. Prevents dangerous swings between dehydration and hyponatremia at home.
  3. Enables early self-referral and protects unconscious patients in emergencies via medical alert ID.
Before discharge, patient accurately demonstrated desmopressin spray technique, explained both dehydration and hyponatremia warning signs, and ordered a medical alert ID.

Detailed Nursing Assessments, Surveillance, and Interventions

  • Fluid Balance and Weight Monitoring: Maintain strict 24-hour intake and output charts (in severe acute DI, measure urine output hourly). Weigh the patient daily at the same hour in similar clothing; monitor urine specific gravity (< 1.005 indicates dilute urine; 1.010–1.020 indicates therapeutic response).
  • Neurological & Electrolyte Surveillance: Check vital signs, mucous membranes, skin turgor, capillary refill, and level of consciousness regularly. Monitor serial serum sodium (target 135–145 mmol/L) and watch carefully for the post-pituitary surgery triphasic pattern so sudden transition to SIADH (oliguria + hyponatremia) is caught before water intoxication occurs.
  • Safe Conduct of the Water Deprivation Test: Never allow unsupervised fluid access (check sinks/pitchers in primary polydipsia); weigh hourly and halt the test immediately if weight loss reaches 3–5% or vital signs/neurology deteriorate.
  • Medication & Skin/Fall Safety: Provide non-skid slippers and bedside urinal/commode to prevent nocturia-related falls; inspect perineal skin for moisture irritation; ensure nasal mucosa is clear before intranasal DDAVP administration (if congested/having URI, notify prescriber to switch temporarily to oral/sublingual/parenteral route).

Uganda Clinical Context and References

In Ugandan clinical practice, central diabetes insipidus is most frequently encountered on neurosurgical, medical, and pediatric wards following traumatic brain injury (road traffic accidents), CNS infections (tuberculous/bacterial meningitis), and sellar/pituitary tumours, while lithium, hypercalcemia, hypokalemia, and sickle cell nephropathy contribute to nephrogenic presentations. Because specialized diagnostics such as plasma copeptin, serum/urine osmolality, and brain MRI are concentrated at national and regional referral hospitals (such as Mulago and Mbarara), nurses at Health Centre IVs and General Hospitals play a critical role by tracking 24-hour urine output (> 3 L/day or > 4 mL/kg/hr in children), bedside urine specific gravity (< 1.005 with negative urine glucose), and serum sodium, maintaining safe hydration, and referring promptly for endocrine/neurosurgical confirmation and desmopressin or thiazide–amiloride therapy.

  • Gubbi S, Hannah-Shmouni F, Koch CA, Verbalis JG. Diagnostic Tests for Diabetes Insipidus. In: Feingold KR, et al., eds. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; updated 2024/2025.
  • Fenske W, Refardt J, Chifu I, et al. A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. N Engl J Med. 2018;379(5):428–439.
  • Arima H, Cheetham T, Christ-Crain M, et al. Changing the name of diabetes insipidus: a position statement of the Working Group for Renaming Diabetes Insipidus. Endocr Connect / J Clin Endocrinol Metab. 2022.
  • Ministry of Health, Republic of Uganda. Uganda Clinical Guidelines (UCG) 2023 — Head Injury, Meningitis, Electrolyte Disorders, and Referral Protocols.
  • Herdman TH, Kamitsuru S, Lopes CT (eds). NANDA International Nursing Diagnoses: Definitions and Classification, 2024–2026 (13th ed.). Thieme; 2024.

Leave a Comment

Your email address will not be published. Required fields are marked *

Want notes in PDF? Join our classes!!

Send us a message on WhatsApp
0726113908

Scroll to Top
Enable Notifications OK No thanks